Clinical Trials
3 trialsNCT06095505 2026-06-05
ALISCA-Lung1
Puma Biotechnology, Inc.
Phase 2 Recruiting
NCT07465757 2026-03-12
ALISCA-Lung2
Puma Biotechnology, Inc.
Phase 2 Not yet recruiting
NCT02038647 2018-12-27
Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
Takeda
Phase 2 Completed